MCID: LKM070
MIFTS: 55

Leukemia, Acute Monocytic

Categories: Blood diseases, Cancer diseases

Aliases & Classifications for Leukemia, Acute Monocytic

MalaCards integrated aliases for Leukemia, Acute Monocytic:

Name: Leukemia, Acute Monocytic 57 38
Acute Monocytic Leukemia 12 75 29 55 6 15 17 72
Acute Monoblastic Leukemia and Acute Monocytic Leukemia 12
Acute Monocytic Leukemia Without Mention of Remission 12
M5b Acute Differentiated Monocytic Leukemia 72
Acute Monocytic Leukemia, Morphology 12
Acute Monocytic Leukemia, Fab M5 12
Leukemia, Monocytic, Acute 44

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant somatic cell mutation


HPO:

32
leukemia, acute monocytic:
Inheritance autosomal dominant somatic cell mutation


Classifications:



External Ids:

Disease Ontology 12 DOID:8864
OMIM 57 151380
ICD9CM 35 206.0
MeSH 44 D007948
SNOMED-CT 68 22331004 91859000
MedGen 42 C0023465
UMLS 72 C0023465 C1318544

Summaries for Leukemia, Acute Monocytic

Disease Ontology : 12 A monocytic leukemia where the majority of monocytic cells are promonocytes.

MalaCards based summary : Leukemia, Acute Monocytic, also known as acute monocytic leukemia, is related to monocytic leukemia and myelodysplastic syndrome. An important gene associated with Leukemia, Acute Monocytic is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1), and among its related pathways/superpathways are MAPK signaling pathway and PI3K-Akt signaling pathway. The drugs Mesna and Idarubicin have been mentioned in the context of this disorder. Affiliated tissues include monocytes, myeloid and bone, and related phenotypes are acute monocytic leukemia and growth/size/body region

Wikipedia : 75 Acute monocytic leukemia (AMoL, or AML-M5) is a type of acute myeloid... more...

More information from OMIM: 151380

Related Diseases for Leukemia, Acute Monocytic

Diseases in the Monocytic Leukemia family:

Leukemia, Acute Monocytic Adult Acute Monocytic Leukemia
Chronic Monocytic Leukemia Subacute Monocytic Leukemia

Diseases related to Leukemia, Acute Monocytic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 155)
# Related Disease Score Top Affiliating Genes
1 monocytic leukemia 30.0 KMT2A KAT6A CSF1 CD14
2 myelodysplastic syndrome 28.9 NUP98 NF1 KMT2A CSF1 CREBBP
3 acute leukemia 28.8 MPO MLLT10 KMT2A CREBBP
4 precursor t-cell acute lymphoblastic leukemia 28.7 NUP98 MPO MLLT10 KMT2A
5 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 28.4 MPO KMT2A CSF1 CREBBP
6 hematologic cancer 28.1 NUP98 MLLT10 KMT2A CSF1 CREBBP
7 leukemia, acute myeloid 27.9 NUP98 MPO MLLT10 MALAT1 KMT2A KAT6A
8 adult acute monocytic leukemia 12.9
9 acute monoblastic leukemia 12.1
10 chromosomal triplication 10.5
11 leukemia 10.5
12 polycystic kidney disease, infantile severe, with tuberous sclerosis 10.4 TSC2 PKD1
13 intracranial berry aneurysm 10.4 PKD1 NF1
14 leukemia, acute lymphoblastic 10.2
15 histiocytosis 10.2
16 neutropenia 10.2
17 47,xyy 10.2
18 pfeiffer syndrome 10.1
19 langerhans cell histiocytosis 10.1
20 sarcoma 10.1
21 thrombocytopenia 10.1
22 spindle cell sarcoma 10.1
23 malignant histiocytosis 10.1
24 hematopoietic stem cell transplantation 10.1
25 erythroleukemia, familial 10.1
26 leukemia, chronic myeloid 10.1
27 acute promyelocytic leukemia 10.1
28 disseminated intravascular coagulation 10.1
29 subleukemic leukemia 10.1
30 aleukemic leukemia cutis 10.1
31 b-cell lymphoma 10.1
32 48,xyyy 10.1
33 acute myeloid leukemia with t(8;16)(p11;p13) translocation 10.0 KAT6A CREBBP
34 autosomal genetic disease 10.0 TSC2 PKD1 NF1
35 tuberous sclerosis 10.0 TSC2 STK11 PKD1 NF1
36 leukemia, chronic lymphocytic 10.0
37 down syndrome 10.0
38 myeloma, multiple 10.0
39 aplastic anemia 10.0
40 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.0
41 leukemia, acute lymphoblastic 3 10.0
42 deficiency anemia 10.0
43 exanthem 10.0
44 respiratory failure 10.0
45 pancytopenia 10.0
46 myeloproliferative neoplasm 10.0
47 thrombocytosis 10.0
48 hairy cell leukemia 10.0
49 hypokalemia 10.0
50 severe combined immunodeficiency 10.0

Graphical network of the top 20 diseases related to Leukemia, Acute Monocytic:



Diseases related to Leukemia, Acute Monocytic

Symptoms & Phenotypes for Leukemia, Acute Monocytic

Human phenotypes related to Leukemia, Acute Monocytic:

32
# Description HPO Frequency HPO Source Accession
1 acute monocytic leukemia 32 HP:0004845

Symptoms via clinical synopsis from OMIM:

57
Heme:
acute monocytic leukemia

Clinical features from OMIM:

151380

MGI Mouse Phenotypes related to Leukemia, Acute Monocytic:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.31 CD14 CREBBP CSF1 KAT6A KMT2A NF1
2 hematopoietic system MP:0005397 10.3 CD14 CREBBP CSF1 KAT6A KMT2A MPO
3 cardiovascular system MP:0005385 10.29 CREBBP CSF1 KAT6A KMT2A MPO NF1
4 cellular MP:0005384 10.28 CREBBP CSF1 KAT6A KMT2A MLLT10 NF1
5 homeostasis/metabolism MP:0005376 10.25 CD14 CREBBP CSF1 KAT6A KMT2A MPO
6 immune system MP:0005387 10.24 CD14 CREBBP CSF1 KAT6A KMT2A MPO
7 mortality/aging MP:0010768 10.22 CD14 CREBBP CSF1 KAT6A KMT2A MPO
8 embryo MP:0005380 10.21 CREBBP KAT6A KMT2A NF1 NUP98 PKD1
9 endocrine/exocrine gland MP:0005379 10.2 CREBBP CSF1 KAT6A NF1 NME1 PKD1
10 craniofacial MP:0005382 10.18 CREBBP CSF1 KAT6A KMT2A NF1 PKD1
11 integument MP:0010771 10.18 CREBBP CSF1 KAT6A KMT2A NF1 NME1
12 liver/biliary system MP:0005370 10.09 CREBBP CSF1 KAT6A KMT2A NF1 NME1
13 digestive/alimentary MP:0005381 10.04 CREBBP KAT6A NF1 PKD1 SOS1 STK11
14 muscle MP:0005369 9.97 CREBBP CSF1 KMT2A MPO NF1 PKD1
15 nervous system MP:0003631 9.96 CREBBP CSF1 KAT6A KMT2A NF1 NME1
16 limbs/digits/tail MP:0005371 9.93 CREBBP CSF1 KAT6A KMT2A NF1 PKD1
17 neoplasm MP:0002006 9.87 CREBBP KMT2A NF1 NME1 PKD1 STK11
18 normal MP:0002873 9.7 CREBBP KAT6A KMT2A NF1 PKD1 STK11
19 respiratory system MP:0005388 9.43 CD14 CREBBP CSF1 NF1 PKD1 STK11
20 skeleton MP:0005390 9.23 CD14 CREBBP CSF1 KAT6A KMT2A NF1

Drugs & Therapeutics for Leukemia, Acute Monocytic

Drugs for Leukemia, Acute Monocytic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 217)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mesna Approved, Investigational Phase 3 3375-50-6 598
2
Idarubicin Approved Phase 3 58957-92-9 42890
3
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
4
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
5
Melphalan Approved Phase 3 148-82-3 460612 4053
6
Thioguanine Approved Phase 3 154-42-7 2723601
7
Lenograstim Approved, Investigational Phase 3 135968-09-1
8
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
9
Etoposide Approved Phase 3 33419-42-0 36462
10
Fludarabine Approved Phase 3 21679-14-1, 75607-67-9 30751
11
Arsenic trioxide Approved, Investigational Phase 2, Phase 3 1327-53-3 518740
12
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
13
Busulfan Approved, Investigational Phase 3 55-98-1 2478
14
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
15
leucovorin Approved Phase 3 58-05-9 143 6006
16
alemtuzumab Approved, Investigational Phase 2, Phase 3 216503-57-0
17
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
18
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
19
Carmustine Approved, Investigational Phase 3 154-93-8 2578
20
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
21
Hydroxyurea Approved Phase 3 127-07-1 3657
22
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
23
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
24
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
25
Daunorubicin Approved Phase 3 20830-81-3 30323
26
Clofarabine Approved, Investigational Phase 3 123318-82-1 119182
27
Azacitidine Approved, Investigational Phase 3 320-67-2 9444
28
Decitabine Approved, Investigational Phase 3 2353-33-5 451668
29
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
30
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
31
midostaurin Approved, Investigational Phase 3 120685-11-2 104937 9829523
32
Histamine Approved, Investigational Phase 3 51-45-6 774
33
Cyproheptadine Approved Phase 3 129-03-3 2913
34
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 5538 444795
35
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
36
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
37 Lintuzumab Investigational Phase 3 166089-32-3
38
tipifarnib Investigational Phase 3 192185-72-1 159324
39 Staurosporine Experimental Phase 3 62996-74-1
40 Vaccines Phase 3
41 Antibodies Phase 3
42 Antibodies, Monoclonal Phase 3
43 Immunoglobulins Phase 3
44 Protective Agents Phase 3
45 Radiation-Protective Agents Phase 3
46 Alkylating Agents Phase 3
47 Antirheumatic Agents Phase 3
48 Antineoplastic Agents, Alkylating Phase 3
49 Adjuvants, Immunologic Phase 3
50
asparaginase Phase 3

Interventional clinical trials:

(show top 50) (show all 182)
# Name Status NCT ID Phase Drugs
1 A Phase 3, Randomized, Double-Blind, Multicenter Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF in Elderly Patients With AML in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study Unknown status NCT00454168 Phase 3
2 Gemtuzumab Ozogamicin (GO) Monotherapy Versus Standard Supportive Care for Previously Untreated AML in Elderly Patients Who Are Not Eligible for Intensive Chemotherapy: A Randomized Phase II/III Trial (AML-19) of the EORTC-LG and GIMEMA-ALWP Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
3 Phase III, Randomized, Multicenter Study to Assess the Efficacy and Safety of HuM195 (Recombinant Humanized Anti-CD33 Monoclonal Antibody) in Combination With Standardized Chemotherapy Compared to Standardized Chemotherapy Alone in the Treatment of Patients With Refractory or First-Relapsed Acute Myelogenous Leukemia (AML) Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
4 The Value of High Dose Versus Standard Dose ARA-C During Induction and of IL-2 After Intensive Consolidation/Autologous Stem Cell Transplantation in Patients (Age 15-60 Years) With Acute Myelogenous Leukemia. A Randomized Phase II Trial of the EORTC and the GIMEMA-ALWP Unknown status NCT00004128 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide
5 RANDOMIZED PHASE III STUDY OF INDUCTION (ICE VS MICE VS DCE) AND INTENSIVE CONSOLIDATION (IDIA VS NOVIA VS DIA) FOLLOWED BY BONE MARROW TRANSPLANTATION IN ACUTE MYELOGENOUS LEUKEMIA: AML 10 PROTOCOL Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
6 ACUTE MYELOID LEUKAEMIA TRIAL 12 Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
7 High-Dose Cytarabine and Idarubicin Induction, High Dose Etoposide and Cyclophosphamide Intensification, Autologous Stem Cell Transplantation and Interleukin-2 Immune Modulation in Previously Untreated De Novo and Secondary Adult Myeloid Leukemia Completed NCT00002945 Phase 3 cyclophosphamide;cytarabine;etoposide;idarubicin;melphalan
8 A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission Completed NCT00093470 Phase 3 Tipifarnib
9 A Phase III Study of Flt3 Ligand (Flt3L) Therapy in Acute Myeloid Leukemia (AML) Patients in Remission Completed NCT00006223 Phase 3
10 Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
11 Phase III Study of MDR Modulation With PSC-833 (NSC #648265) Followed by Immunotherapy With rIL-2 (NSC #373364) vs. No Further Therapy in Previously Untreated Patients With AML >60 Years Completed NCT00003190 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar
12 A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML) Completed NCT01307579 Phase 3 Caspofungin Acetate;Fluconazole
13 A Phase III Randomized of Cloretazine™ (VNP40101M) and Cytosine Arabinoside (AraC) in Patients With Acute Myeloid Leukemia in First Relapse Completed NCT00112554 Phase 3 cytarabine;laromustine
14 Gemtuzumab Ozogamicin (GO) Combined With Standard Intensive Chemotherapy Versus Standard Intensive Chemotherapy Alone For Induction/Consolidation In Patients 61-75 Years Old With Previously Untreated AML: A Randomized Phase III Trial (AML-17) Of The EORTC-LG and the GIMEMA-ALWP Completed NCT00052299 Phase 3 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
15 RANDOMIZED PHASE III STUDY TO EVALUATE THE VALUE OF rHuG-CSF IN INDUCTION AND OF AN ORAL SCHEDULE AS CONSOLIDATION TREATMENT IN ELDERLY PATIENTS WITH ACUTE MYELOGENOUS LEUMEKIA (AML-13 PROTOCOL) Completed NCT00002719 Phase 3 amsacrine;carmustine;cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
16 IDA VS MTZ IN INDUCTION AND INTENSIFICATION TREATMENT OF AML OR MDS IN CHILDREN, A PHASE III RANDOMIZED STUDY Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
17 A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
18 The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
19 Phase III Randomized Study of Induction Chemotherapy With or Without MDR-Modulation With PSC-833 (NSC # 648265, IND # 41121) Followed by Cytogenetic Risk-Adapted Intensification Therapy Followed by Immunotherapy With rIL-2 (NSC # 373364, IND # 1969) vs. Observation in Previously Untreated Patients With AML < 60 Years Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
20 A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg®) During Induction Therapy Versus Standard Induction With Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy With Gemtuzumab Ozogamicin (Mylotarg®) or No Additional Therapy For Patients Under Age 61 With Previously Untreated De Novo Acute Myeloid Leukemia (AML) Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
21 Randomised Induction and Post Induction Therapy in Older Patients (≥61 Years of Age) With Acute Myeloid Leukemia (AML) and Refractory Anemia With Excess Blasts (RAEB, RAEB-t) Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
22 A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
23 Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
24 A Randomized, Placebo-Controlled, Double Blind, Trial of the Administration of the MDR Modulator, Zosuquidar Trihydrochloride (LY335979), During Conventional Induction and Post-Remission Therapy in Patients Greater Than 60 Years of Age With Newly Diagnosed Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts in Transformation or High-Risk Refractory Anemia With Excess Blasts Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
25 A PHASE III STUDY IN CHILDREN WITH UNTREATED ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
26 A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
27 A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML) Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
28 Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age &gt;/= 60 Years) Active, not recruiting NCT02085408 Phase 3 clofarabine;daunorubicin hydrochloride;cytarabine;decitabine
29 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
30 Treatment of Relapsed Acute Myelogenous Leukemia Consisting of Intermediate Dose Cytosine Arabinoside (ARA-C) Plus Interspaced Continuous Infusion Idarubicin, Followed by Continuous Infusion of Low-Dose ARA-C, A Phase II Study by the EORTC-LCG Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
31 Treatment Protocol for Patients With Standard Risk Acute Myelogenous Leukemia and Its Variants: Induction Using High-Dose Cytarabine, Mitoxantrone and Ethyol; Consolidation With Cytarabine and Idarubicin and Maintenance With 13 Cis Retinoic Acid and Alpha Interferon Unknown status NCT00003405 Phase 2 amifostine trihydrate;bromodeoxyuridine;cytarabine;idarubicin;idoxuridine;isotretinoin;mitoxantrone hydrochloride
32 A Phase I/II Study of Lenalidomide Maintenance After Autologous Stem Cell Transplant for Elderly Patients With Acute Myeloid Leukemia (AML) Unknown status NCT02038153 Phase 1, Phase 2 Lenalidomide
33 Phase II, Open-Label Study of HuM195 (Humanized Anti-CD33 Monoclonal Antibody) Administered to Patients With Acute Myelogenous Leukemia (AML) Who Are Documented Regimen Failures (RF) of the Control Arm of Study 195-301 Unknown status NCT00006084 Phase 2
34 A Phase II Study of Cloretazine® (VNP40101M) for Elderly Patients With De Novo Poor Risk Acute Myelogenous Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
35 Clofarabine in Combination With a Standard Remission Induction Regimen (AraC and Idarubicin) in Patients 18-60 Years Old With Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS) : a Phase I-II Study of the EORTC-LG and GIMEMA (AML-14A Trial) Unknown status NCT00838240 Phase 1, Phase 2 clofarabine;cytarabine;idarubicin
36 A Phase 2 Study of the AKT Kinase Inhibitor MK-2206 in Patients With Relapsed Refractory Acute Myelogenous Leukemia Completed NCT01253447 Phase 2 Akt inhibitor MK2206
37 Autologous Bone Marrow Transplantation for Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome - A Phase II Pilot Study Completed NCT00004899 Phase 2 busulfan;etoposide
38 Phase II Study of Alvocidib (NSC 649890, Flavopiridol) in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Newly Diagnosed, Previously Untreated, Poor-Risk Acute Myelogenous Leukemias Completed NCT00407966 Phase 2 alvocidib;cytarabine;mitoxantrone hydrochloride
39 A Randomized Phase II Study of Nuclear Factor-kappa B (NF-κB) Inhibition During Induction Chemotherapy for Patients With Acute Myelogenous Leukemia Completed NCT02144675 Phase 2 choline magnesium trisalicylate;idarubicin;cytarabine
40 A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Acute Myeloid Leukemia (AML) Completed NCT00305773 Phase 2 vorinostat;vorinostat
41 A Phase II Study of Lenalidomide (REVLIMID, NSC-703813) for Previously Untreated Non-M3, Deletion 5q Acute Myeloid Leukemia (AML) in Patients Age 60 or Older Who Decline Remission Induction Chemotherapy Completed NCT00352365 Phase 2 lenalidomide
42 A Randomized Phase II Trial of Tipifarnib (R115777, ZARNESTRA, NSC #702818) in Combination With Oral Etoposide (VP-16) in Elderly Adults With Newly Diagnosed, Previously Untreated Acute Myelogenous Leukemia (AML) Completed NCT00602771 Phase 2 tipifarnib;etoposide
43 Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio Completed NCT01361464 Phase 2 Tipifarnib
44 A Phase 1/2 Study of Vorinostat (Zolinza®) in Combination With Gemtuzumab Ozogamicin (Mylotarg®) and Azacitidine (Vidaza®) in Patients 50 Years of Age and Older With Relapsed/Refractory Non-APL Acute Myeloid Leukemia (AML) Completed NCT00895934 Phase 1, Phase 2 vorinostat;gemtuzumab ozogamicin;azacitidine
45 5-Azacytidine to Treat Acute Myeloid Leukemia in Elderly or Frail Patients Not Suitable for Intensive Chemotherapy. A Multicenter Phase II Trial. Completed NCT00739388 Phase 2 azacytidine
46 Phase II Trial of Arsenic Trioxide in Relapsed and Refractory Acute Myeloid Leukemia, Secondary Leukemia, and/or Newly-Diagnosed Patients Greater Than or Equal to 65 Years Old Completed NCT00005795 Phase 2 arsenic trioxide
47 PHASE II STUDY EVALUATING AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION FOR ACUTE LEUKEMIAS Completed NCT00002567 Phase 2 etoposide
48 A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia Completed NCT01656031 Phase 2 clofarabine;cytarabine
49 Phase II Trial Utilizing Idarubicin in Combination With High Dose Ara-C for Induction Therapy for Adult Acute Myelogenous Leukemia (AML) Completed NCT00528398 Phase 2 cytarabine;idarubicin
50 Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside (Ara-C) With and Without the Checkpoint Kinase 1 (CHK1) Inhibitor MK-8776 in Adults With Relapsed AML Completed NCT01870596 Phase 2 Cytarabine;CHK1 Inhibitor SCH 900776

Search NIH Clinical Center for Leukemia, Acute Monocytic

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Daunorubicin

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Acute Monocytic cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Leukemia, Acute Monocytic:
NiCord, umbilical cord blood-derived stem/progenitor cells for hemotological diseases
Embryonic/Adult Cultured Cells Related to Leukemia, Acute Monocytic:
Umbilical cord blood-derived stem cells (NiCord) PMIDs: 22198152

Cochrane evidence based reviews: leukemia, monocytic, acute

Genetic Tests for Leukemia, Acute Monocytic

Genetic tests related to Leukemia, Acute Monocytic:

# Genetic test Affiliating Genes
1 Acute Monocytic Leukemia 29

Anatomical Context for Leukemia, Acute Monocytic

MalaCards organs/tissues related to Leukemia, Acute Monocytic:

41
Monocytes, Myeloid, Bone, Bone Marrow, T Cells, Endothelial, Skin

Publications for Leukemia, Acute Monocytic

Articles related to Leukemia, Acute Monocytic:

(show top 50) (show all 895)
# Title Authors PMID Year
1
Familial monocytic leukaemia. A report of two families. 8
295149 1979
2
The MYO1F, unconventional myosin type 1F, gene is fused to MLL in infant acute monocytic leukemia with a complex translocation involving chromosomes 7, 11, 19 and 22. 9 38
15897884 2005
3
Is t(10;11)(p11.2;q23) involving MLL and ABI-1 genes associated with congenital acute monocytic leukemia? 9 38
12547160 2002
4
Involvement of the NUP98 gene in a chromosomal translocation t(11;20)(p15;q11.2) in a patient with acute monocytic leukemia (FAB-M5b). 9 38
11530805 2001
5
Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a t(8;22)(p11;q13) chromosome translocation. 9 38
11243405 2001
6
[In vitro growth and clinical response of leukemia cells to macrophage colony-stimulating factor (M-CSF) and granulocyte colony-stimulating factor (G-CSF) in acute leukemia]. 9 38
10897214 2000
7
MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). 9 38
10824998 2000
8
Acute monocytic leukemia with a novel 10;11 rearrangement resolved by fluorescence in situ hybridization. 9 38
10731585 2000
9
Molecular analysis of the rearranged genome and chimeric mRNAs caused by the t(6;11)(q27;q23) chromosome translocation involving MLL in an infant acute monocytic leukemia. 9 38
10719372 2000
10
Involvement of the MLL and RARalpha genes in a patient with acute monocytic leukemia with t(11;17)(q23;q12) 9 38
10720155 2000
11
Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2. 9 38
9731070 1998
12
Evaluation by multivariate analysis of the differentiation inhibitory factor nm23 as a prognostic factor in acute myelogenous leukemia and application to other hematologic malignancies. 9 38
9490665 1998
13
Induction of interleukin-12 p40 transcript by CD40 ligation via activation of nuclear factor-kappaB. 9 38
9464836 1997
14
[Detection of MLL gene rearrangement in acute myelomonocytic and monocytic leukemia]. 9 38
10743082 1997
15
Differentiation inhibitory factor nm23 as a new prognostic factor in acute monocytic leukemia. 9 38
8896423 1996
16
Successful treatment of a 93-year-old patient with hypoplastic acute monocytic leukemia using macrophage colony-stimulating factor. 9 38
7758063 1995
17
Prevalence and clinical correlations of MLL gene rearrangements in AML-M4/5. 9 38
7949133 1994
18
A case of acute monocytic leukemia with t(11;17) involving a rearrangement of MLL-1 and a region proximal to the RARA gene. 9 38
8194047 1994
19
[Molecular diagnosis of leukemia and lymphoma]. 9 38
8176845 1994
20
Molecular characterization of the gene for human interleukin-1 beta converting enzyme (IL1BC). 9 38
8034320 1994
21
MLLT3 gene on 9p22 involved in t(9;11) leukemia encodes a serine/proline rich protein homologous to MLLT1 on 19p13. 9 38
8414510 1993
22
A novel translocation, t(9;11)(q33;q23) involving the HRX gene in an acute monocytic leukemia. 9 38
8019892 1993
23
D-4F, an apolipoprotein A-I mimetic, suppresses IL-4 induced macrophage alternative activation and pro-fibrotic TGF-β1 expression. 38
31335245 2019
24
[The value of detecting MLL gene rearrangement in children with acute monocytic leukemia]. 38
31400126 2019
25
Cytogenetics and associated mutation profile in patients with acute monocytic leukemia. 38
31099482 2019
26
MicroRNA‑217 is involved in the progression of atherosclerosis through regulating inflammatory responses by targeting sirtuin 1. 38
31432137 2019
27
Priming with GM-CSF instead of G-CSF enhances CAG-induced apoptosis of acute monocytic leukemia cells in vitro. 38
31115604 2019
28
Characteristic genes in THP‑1 derived macrophages infected with Mycobacterium tuberculosis H37Rv strain identified by integrating bioinformatics methods. 38
31364746 2019
29
Molecular hydrogen suppresses free radical-induced cell death by mitigating fatty acid peroxidation and mitochondrial dysfunction. 38
31295412 2019
30
Making it stick: A CURE designed to introduce students to the scientific process and the host response to foreign materials. 38
31002463 2019
31
Red blood cells participate in reverse cholesterol transport by mediating cholesterol efflux of high-density lipoprotein and apolipoprotein A-I from THP-1 macrophages. 38
31188743 2019
32
[Cloning of New Antigen Gene MLAA-34 Promoter and Identification of Core Region in Acute Monocytic Leukemia]. 38
31204911 2019
33
Pd(II) complexes with N-heteroaromatic hydrazone ligands: Anticancer activity, in silico and experimental target identification. 38
31299379 2019
34
[Characterizing the molecular cytogenetics in acute monocytic leukemia]. 38
31055804 2019
35
Ets1 Plays a Critical Role in MLL/EB1-Mediated Leukemic Transformation in a Mouse Bone Marrow Transplantation Model. 38
30974389 2019
36
Extracellular Vesicles from Interferon-γ-primed Human Umbilical Cord Mesenchymal Stromal Cells Reduce Escherichia coli-induced Acute Lung Injury in Rats. 38
30870158 2019
37
Eutopic endometrium from patients with endometriosis modulates the expression of CD36 and SIRP-α in peritoneal macrophages. 38
30843336 2019
38
Albiflorin inhibits the formation of THP-1-derived foam cells through the LOX-1/NF-κB pathway. 38
30371044 2019
39
HMGB1 from Lampetra japonica promotes inflammatory activation in supraneural body cells. 38
30423344 2019
40
Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplantation: a case report. 38
30885156 2019
41
Downregulation of LPXN expression by siRNA decreases the malignant proliferation and transmembrane invasion of SHI-1 cells. 38
30655748 2019
42
Oxidized LDL, homocysteine, homocysteine thiolactone and advanced glycation end products act as pro-oxidant metabolites inducing cytokine release, macrophage infiltration and pro-angiogenic effect in ARPE-19 cells. 38
31086404 2019
43
Analysis of Comparative Proteomic and Potent Targets of Peniciketal A in Human Acute Monocytic Leukemia. 38
30747080 2019
44
Tanshinone IIA induces apoptosis and autophagy in acute monocytic leukemia via downregulation of PI3K/Akt pathway. 38
31217869 2019
45
Spontaneous remission of acute monocytic leukemia with trisomy 8 and trisomy 18. 38
31257350 2019
46
Differential Immunomodulatory Effect of Graphene Oxide and Vanillin-Functionalized Graphene Oxide Nanoparticles in Human Acute Monocytic Leukemia Cell Line (THP-1). 38
30634552 2019
47
Facial paralysis as a presenting symptom of infant leukemia: A case report and literature review. 38
30572489 2018
48
Advanced microRNA-based cancer diagnostics using amplified time-gated FRET. 38
30542553 2018
49
MLL-PTD in a 13-year-old patient with blast phase myeloproliferative neoplasm: A case report. 38
30431598 2018
50
Regulatory roles of miR-155 and let-7b on the expression of inflammation-related genes in THP-1 cells: effects of fatty acids. 38
29790117 2018

Variations for Leukemia, Acute Monocytic

ClinVar genetic disease variations for Leukemia, Acute Monocytic:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 STK11 NM_000455.4(STK11): c.970C> G (p.Pro324Ala) single nucleotide variant Conflicting interpretations of pathogenicity rs549474196 19:1223033-1223033 19:1223034-1223034
2 NF1 NM_000267.3(NF1): c.1588G> A (p.Val530Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs145191978 17:29546083-29546083 17:31219065-31219065
3 NF1 NM_000267.3(NF1): c.2747A> G (p.Asn916Ser) single nucleotide variant Uncertain significance rs765043916 17:29556380-29556380 17:31229362-31229362
4 TSC2 NM_000548.5(TSC2): c.5336A> G (p.Gln1779Arg) single nucleotide variant Benign/Likely benign rs748947919 16:2138523-2138523 16:2088522-2088522
5 SOS1 NM_005633.3(SOS1): c.2371C> A (p.Leu791Ile) single nucleotide variant Benign rs142004123 2:39239286-39239286 2:39012145-39012145

Copy number variations for Leukemia, Acute Monocytic from CNVD:

7 (show all 23)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 21832 1 16200000 20400000 Gain Acute monocytic leukemia
2 31525 1 28000000 30200000 Gain Acute monocytic leukemia
3 61776 12 10100000 12800000 Loss Acute monocytic leukemia
4 90243 15 20700000 25700000 Gain Acute monocytic leukemia
5 93369 15 52900000 59100000 Gain Acute monocytic leukemia
6 108855 17 23200000 28800000 Deletion NF1 Acute monocytic leukemia
7 110292 17 31800000 38100000 Gain Acute monocytic leukemia
8 116498 17 67100000 70900000 Loss Acute monocytic leukemia
9 125458 19 13900000 20000000 Gain Acute monocytic leukemia
10 133734 19 6900000 13900000 Gain Acute monocytic leukemia
11 140901 2 203300000 204900000 Loss Acute monocytic leukemia
12 188152 4 59500000 66600000 Loss Acute monocytic leukemia
13 190404 4 88000000 93700000 Loss Acute monocytic leukemia
14 191655 5 1 4500000 Gain Acute monocytic leukemia
15 196530 5 168500000 172800000 Gain Acute monocytic leukemia
16 201329 5 68400000 73300000 Gain Acute monocytic leukemia
17 206333 6 139000000 142800000 Loss Acute monocytic leukemia
18 219029 7 121100000 123800000 Loss Acute monocytic leukemia
19 224721 7 37200000 43300000 Loss Acute monocytic leukemia
20 226783 7 61700000 67000000 Loss Acute monocytic leukemia
21 226785 7 61700000 77500000 Loss Acute monocytic leukemia
22 243519 8 84600000 86900000 Gain Acute monocytic leukemia
23 250024 9 19900000 25600000 Loss Acute monocytic leukemia

Expression for Leukemia, Acute Monocytic

Search GEO for disease gene expression data for Leukemia, Acute Monocytic.

Pathways for Leukemia, Acute Monocytic

GO Terms for Leukemia, Acute Monocytic

Cellular components related to Leukemia, Acute Monocytic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.7 TSC2 STK11 PKD1 NUP98 NME1 NF1
2 histone acetyltransferase complex GO:0000123 8.62 KAT6A CREBBP

Biological processes related to Leukemia, Acute Monocytic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.46 TSC2 STK11 NME1 NF1
2 positive regulation of transforming growth factor beta receptor signaling pathway GO:0030511 9.26 STK11 CREBBP
3 protein acetylation GO:0006473 8.96 KAT6A CREBBP
4 anoikis GO:0043276 8.62 TSC2 STK11

Molecular functions related to Leukemia, Acute Monocytic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.77 TSC2 STK11 SOS1 PKD1 NUP98 NME1
2 acetyltransferase activity GO:0016407 8.62 KAT6A CREBBP

Sources for Leukemia, Acute Monocytic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....